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ABSTRACT
Objective: This study aimed to describe the synthesis and biological/pharmacokinetic potential of the 1,3-diisobutoxypropan-2-yl nitrate (NDIBP) 
using in silico and ex vivo approaches.
Methods: The compound was characterized by Fourier-transform infrared spectroscopy and 1H and 13C- nuclear magnetic resonance spectra. NDIBP 
biological activity spectrum was obtained by Prediction of Activity Spectra for Substances (PASS). The pharmacological effect was validated in ex vivo 
studies using mesenteric artery. Drug-like properties and Absorption Distribution Metabolism Excretion and Toxicity (ADMET) studies were carried 
out by pkCSM (Predicting Small-Molecule Pharmacokinetic Properties Using Graph-Based Signatures) software.
Results: PASS prediction indicated NDIBP as nitric oxide (NO) donor with vasodilator effect. Ex vivo studies validated PASS analysis and showed the 
NDIBP vasorelaxant activity in mesenteric arteries. Physicochemical parameters and ADMET prediction suggested that NDIBP is a drug-like molecule 
with a good theoretical oral bioavailability, good absorption in the gastrointestinal tract, and a low distribution in the tissues.
Conclusion: All the data indicated that NDIBP possesses biological activities and drug-like properties to be considered as a vasorelaxant agent and a 
good candidate for further investigation in the treatment of arterial hypertension and drug development studies.
Keywords: Organic nitrate, Prediction of Activity Spectra for Substances, ADME, Hypertension, Mesenteric artery.
INTRODUCTION
Arterial hypertension (AH) has become the most prevalent chronic 
disease in the world [1] and is considered the main risk factor for 
the development of a range of other cardiovascular diseases, such as 
coronary diseases, stroke, and renal failure [2]. The endothelium-
dependent vasorelaxation is normally reduced in hypertension due 
to alterations in the homeostatic regulation of vascular tone known 
as endothelial dysfunction [3,4]. This process is mainly attributed to 
impairment on nitric oxide (NO) production and bioavailability in the 
vascular wall and increased NO degradation due to the rise in oxidative 
stress leading to increase in vascular resistance [5-7].
Therapy with organic nitrates such as nitroglycerine (GTN) and 
isosorbide dinitrate (ISDN) has been used for many years in the 
treatment of cardiovascular disorders including AH [8]. These drugs 
release NO from its structures and replace the NO deficiency leading 
to improvement of the endothelial function and modulation of the 
vascular tone, reducing AH, and its comorbidities [2,9-12]. Despite the 
benefits, these NO donors have limitations that include high reactivity, 
short half-life, and induction of the tolerance phenomenon [13,14], 
limiting their efficient clinical use [15]. Therefore, the search for new 
promising organic nitrates with the absence of those undesirable 
effects and presenting desirable pharmacological characteristics to 
treat AH is still a scientific challenge. To obtain a new compound, we 
synthetized the novel NO donor 1,3-diisobutoxypropan-2-yl nitrate 
(NDIBP). Once this molecule is a novel organic nitrate and its biological 
and pharmacokinetics characteristics are unknown, a virtual screening 
of NDIBP is a good approach to determine its initial profile and verify 
the chance to be used in cardiovascular field.
Computational techniques such as Prediction of Activity Spectra 
for Substances (PASS) and pkCSM (Predicting Small-Molecule 
Pharmacokinetic Properties Using Graph-Based Signatures) have 
become important tools in medicinal chemistry to predict the 
biological activities and pharmacokinetics (PK) properties of a specific 
compound based exclusively in its structure and physicochemical 
properties [16-18]. The in silico assessment of the biological aspects 
determines the most correct direction for pharmacological studies 
of the new substance, reducing both cost and time required to 
perform in vitro screenings [19-23]. In addition, these new approach 
methodologies (NAMs) could help to justify the ethical principles of 3Rs 
(reduce, refine, and replace) by avoiding unnecessary animal studies, 
reducing the number of animals used in the research, and refining the 
protocol to a minimum level of animal pain, distress, or suffering [24].
Although the pharmacological properties are important factors for 
drug discovery, the PK aspects are the main responsible to predict if the 
drug will advance its effectiveness and safety aiming the therapeutic 
success [25]. The in silico studies to predict Absorption Distribution 
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Metabolism Excretion and Toxicity (ADMET) properties help in the 
analysis of novel substances to avoid spending time on candidates 
that would be toxic or metabolized by body enzymes into an inactive 
or unable form to cross cell membranes and thus work with only 
promising compounds [26,27].
Therefore, using in silico techniques and validation of the predicted 
potential by ex vivo experiments, this study aimed to explore the 
pharmacological and PK aspects of NDIBP as a candidate for a new NO 
donor. Our study showed that NDIBP has the biological and predicted 
pharmacokinetic characteristics to be a promising drug candidate 




NDIBP was obtained from glycerin by organic synthesis at the 
Department of Chemistry at the Federal University of Paraíba. The 
reaction is illustrated in Fig. 1a. Briefly, an aliquot of dry glycerin 
(1) was transferred to a three-neck round bottom flask, heated at 
100–110°C for 12 h to remove humidity and then hydrochloric acid 
was bubbled in the flask through a tubular system to obtain the 
1,3-dichloropropan-2-ol (3). To produce the gaseous HCl, 100 mL of 
sulfuric acid (12 N) was dropped over slurry of sodium chloride (100 g) 
and hydrochloric acid (36.5%, 2 mol). The reaction finished when the 
absorption of HCl (g) by glycerin not occurred anymore (usually at 
the end of absorption occurs a 25% increase in the initial volume of 
glycerin). Afterward 1,3-dichloropropan-2-ol (3) was purified using 
a fractional distillation at 174–176°C obtaining 70% yield. In second 
step, sodium alkoxide (4) was obtained by mixing sodium metal (2 mol, 
finely cut) in a flask containing 1 mol of the corresponding alcohol (2) 
under constant stirring up to the total sodium added consumption. 
Sodium alkoxide (4; 2 mol) was placed in a round bottom flask and 
1 mol of 1,3-dichloropropan-2-ol (3) was added dropwise under 
continuous stirring for 6 h to synthesize the corresponding oxyalcohol: 
1,3-diisobutoxypropan-2-ol (5). This compound was purified using 
a fractional distillation under vacuum at 185–190°C with a 91% 
reaction yield and then thin-layer chromatography (TLC) and nuclear 
magnetic resonance (NMR) were used to evaluate the purity. Finally, 
to obtain the organic nitrate (6) a reaction using an aliquot of 0.5 mol 
of compound (5) and 0.6 mol of acetic anhydride was performed in a 
round bottom flask and fuming HNO3 (0.6 mol) was added dropwise to 
obtain the NDIBP (6) (Fig. 1b). This mixture was kept under constant 
stirring and in an ice bath for temperature control (5°C). The reaction 
was interrupted with the addition of 100 mL of ice-cold distilled 
water resulting in the formation of a biphasic system. Aqueous phase 
was separated through separation funnel and neutralized by adding 
sodium bicarbonate while organic phase containing the nitrate was 
solubilized in chloroform and dried with anhydrous sodium sulfate to 
remove humidity [28,29]. Chloroform was subsequently removed by 
rotoevaporation. The organic nitrate (6) was storage in the darkness at 
5°C and after 45 days TLC, Fourier-transform infrared (FTIR) and NMR 
confirmed that the purity remains stable.
1,3-dichloropropan-2-ol (3): yield: 70%; IR (ATR) ν/ cm-1 3460 (O-
H), 2992, 1438 (C – H), 1270 (C – O), 851, 733 (C – Cl); 1H NMR (200 
MHz, CDCl3) δ 4.02 (p, 1H), 3.64 (d, 4H), 2.65 (s, 1H); 13C NMR (50 MHz, 
CDCl3) 70.6, 45.5).
1,3-diisobutoxypropan-2-ol (5): yield: 91%; RMN 1H e 13C. IR (ATR) ν/
cm-1 3466 (O-H), 2951, 2867, 1466 (C–H), 1109 (C–O); 1H NMR (200 
MHz, CDCl3) δ 4.03 – 3.83 (p, 1H), 3.52 – 3.38 (d, 4H,), 3.21 (d, 4H), 2.59 
(s, 1H, O-H), 1.85 (m, 2H), 0.88 (d, 12H); 13C NMR (50 MHz, CDCl3) 77.6, 
71.2, 66.7, 27.6, 18.5).
1,3-diisobutoxypropan-2-yl nitrate (6; NDIBP): yield: 85.7%; IR (ATR) 
ν/ cm-1 2956, 2872, 1469 (C–H), 1633, 1274, 850 (N–O), 1107 (C–O). 
1H NMR (200 MHz, CDCl3): δ 3.95 (dt, J = 10.9, 5.4 Hz, 1H, H-1), 3.47 
(dd, J = 5.4, 2.7 Hz, 4H, H-3, H-3’), 3.23 (d, J = 6.7 Hz, 4H, H-2, H-2’), 1.87 
Fig. 1: Synthetic route and structural formulae for 1,3-diisobutoxypropan-2-yl nitrate. (a) Shows the synthetic reaction used to obtain 
NDIBP. The reaction yield was 85,7%. (1) Dry glycerin; (2) corresponding alcohol; (3) 1,3-dichloropropan-2-ol; (4) sodium alkoxide; 
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(tt, J = 13.4, 6.9 Hz, 2H, H-4, H-4’), 0.90 (d, J = 6.7 Hz, 12H, H-5, H-5’). 13C 
NMR (50 MHz, CDCl3): δ 84.4 (C-1), 76.9 (C-3), 71.9 (C-2), 25.1 (C-4), 
22.7 (C-5).
Prediction of NDIBP (1,3-diisobutoxypropan-2-yl nitrate) 
biological activity spectrum by PASS analysis
Prediction of NDIBP biological activity was obtained through PASS 
analysis. This program was designed to access the overall biological 
potential of a molecule [18] and uses the 2D structural formula 
of the compound as the basis for structure description [30-32]. 
This in silico tool can estimate simultaneously over 7000 kind of 
probable pharmacological effects, mechanisms of action, and specific 
toxicities including carcinogenicity, mutagenicity, teratogenicity, and 
embryotoxicity, adverse effects, interaction with metabolic enzymes 
and the influence on gene expression [30,31,33-36]. The set of all 
these characteristics predicted by PASS is termed “biological activity 
spectrum,” an intrinsic characteristic of the compound based exclusively 
in its structure and physicochemical properties [16,17]. PASS approach 
involved the SAR analysis of the training set containing about one 
million of drugs, drug-candidates, leads, and toxic compounds that 
were collected from several data sources including publications, 
patents, chemical databases, and private communications [32,37]. In 
the training set the “active” compounds are those with quantitative 
characteristics of activity better than 10−4 M and the compounds 
less active or with unknown activity are considered as “inactive” [32]. 
Construction of the NDIBP chemical structure and SAR models with the 
compounds from the training set were based on original descriptors 
of multilevel neighborhoods of atoms (MNA). These descriptors are 
a linear notation of atom-centered fragments in the structure of an 
organic molecule and not specify the bond types presented in the 
compound but includes hydrogen atoms according to the partial charge 
and valence of the atoms [38,39]. The algorithm to construct SAR models 
using the compounds from the training set and predict the activities 
was based on the Bayesian estimates [40,41]. PASS software predicted 
qualitatively the biological activity spectrum of NDIBP in terms of 
probability of being active (Pa) and the probability of being inactive 
(Pi) [40]. Values of Pa and Pi can vary between 0 and 1 and in general 
Pa + Pi < 1 when the probabilities are calculated independently [16,30]. 
Most probable activities are characterized by Pa values close to 1, and Pi 
values close to 0.16 Interpretation of the results is flexible and depends 
on the purpose of the study. By default, only activities with Pa>Pi value 
are used as a threshold for possible activities of a new compound which 
provides the mean accuracy of about 95% [34,42,43]. The Pa index just 
reflected the similarity of the studied compound with the structure of 
active molecules presented in the corresponding subset of training set 
and is not related to quantitative activity characteristics [31,32].
Effects of NDIBP on isolated mesenteric arteries contracted with 
phenylephrine
Male Wistar rats (250–300 g) were used for this protocol. They were 
housed in cages under controlled conditions of temperature (21±1°C), a 
12 h light-dark cycle and were allowed food and water ad libitum. After 
euthanasia, the cranial mesenteric artery of the normotensive animals 
was collected, dissected, and sectioned to obtain arterial rings (2–3 mm). 
These preparations were mounted on two Δ-shaped stainless-steel 
wires attached to a tension transducer (PowerLab™, ADInstruments, 
MA, EUA) to assess changes in isometric tone. All the rings were kept 
in 10 mL tissue chambers filled with Tyrode´s solution, gassed with 
carbogenic mixture (95% O2 and 5% CO2) and maintained at 37°C. 
Each ring was stabilized under 0.75 g resting tension for 60 min. After 
stabilization period, tissue viability was verified by a contraction to 
phenylephrine (10 μM) added to the bath and the presence of functional 
endothelium was assessed by the response of relaxation induced by Ach 
(10 μM). Mesenteric rings with vasorelaxation percentage less than 
10% represent an absence of functional endothelium [12]. After the 
initial procedures, mesenteric artery rings (n=6) were pre-contracted 
using phenylephrine (1 μM). When contraction plateau was reached, 
cumulative concentrations of vehicle or NDIBP (10-12–10-4 M) were 
added to the organ bath to build a concentration-response curve. 
NDIBP was previously emulsified with Cremophor® and then mixed 
with distilled water. Initial solution was subsequently diluted to obtain 
the desired concentrations. Final concentration of Cremophor® never 
exceeded 0.01%. The effect was expressed as percentage of relaxation 
in relation to the phenylephrine contraction. Maximum effect (ME) 
was calculated using GraphPad Prism v. 5.01. ME reflects the efficacy 
of the drug [44,45]. This experimental study was approved by the 
Federal University of Paraíba Animal Care and Use Committee (CEUA/
UFPB, Protocol ID: 094/2017 – 10/05/2017) in João Pessoa, Brazil, 
and conducted in accordance with the standards and ethical principles 
of experimentation established by the National Council of Animal 
Experimentation Control (CONCEA).
Computational assessment of the drug-like properties of NDIBP 
NDIBP physicochemical properties, PK aspects, and toxicity profile 
were determined using an ADMET descriptors algorithm protocol 
of pkCSM that uses the concept of graph-based structural signatures 
to predict and optimize ADMET aspects [25]. This software has been 
used as evidence to train accurate molecular predictors of important 
physicochemical parameters such as molecular weight (MW), 
topological polar surface area (TPSA), partition coefficient (octanol-
water) – LogP, number of hydrogen bond acceptor (nHBA), number of 
hydrogen bond donors (nHBD), and rotable bonds (ROTB). Analysis 
of these aspects was used to verify the drug-likeness properties of 
NDIBP based on the guidelines of the Lipinski´s Rule of Five (Lipinski’s 
RO5) [46]. Absorption properties were analyzed based on membrane 
permeability (indicated by colon cancer cell line (Caco-2) permeability), 
human intestinal absorption (HIA), skin permeability, and the 
categorical classification of NDIBP as a P-glycoprotein efflux substrate 
or nonsubstrate. Distribution of the drug was predicted according 
the blood-brain barrier permeability (logBB) and the volume of 
distribution at steady state (VDss). Metabolism property was evaluated 
based on the CYP models for substrate or inhibition (CYP1A2, CYP2C19, 
CYP2C9, CYP2D6, and CYP3A4). Excretion aspect was predicted by the 
total clearance model and the categorical classification of NDIBP as a 
renal OCT2 substrate. Toxicity of NDIBP was obtained based on AMES 
toxicity, hERG I inhibition, hepatotoxicity, and skin sensitization. After 
the results, all the PK parameters were calculated and checked for 
compliance with their standard ranges [47].
Statistical analysis
Data were expressed as the mean±standard error of the mean. 
Statistical analysis was performed using analysis of variance followed 
by the recommended post hoc analysis that was carried out using the 
GraphPad Prisms version 5.01 (GraphPad Software Inc., San Diego, CA, 
USA). Values were considered significantly different when p<0.05.
RESULTS AND DISCUSSION
NDIBP synthesis
The natural source used to obtain NDIBP was glycerin, one of the most 
important co-products of the biodiesel production process and an 
excellent source of C-C to be used in the reaction. NDIBP was synthesized 
from the esterification reaction of the corresponding alcohol using 
concentrated nitric acid in the presence of acetic anhydride (Fig. 1a).
An excess of 20% in the number of moles of nitrating solution (Ac2O/
HNO3) in relation to the stoichiometric amount of the compound 
to be nitrated was used to obtain a higher yield of the new organic 
nitrate. Nitrating solution addition time did not exceed 20 min due 
One of the advantages of this route is the reduced water content in the system since both concentrated nitric acid and acetic anhydride have a very low water amount in their composition and according to Shen et al. [48] the greater is the content of water in reaction medium lower is  the  conversion  rate.  Therefore,  the  chance  of  obtaining  a  higher conversion to  organic  nitrate  was  increased. Suppes  and  Dasari [49] also  recommend  this  synthetic  route  once  the  acetic  anhydride  use instead of sulfuric acid is better due to its higher selectivity, reduced oxidation, and ability to make the reaction at higher temperatures.
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to kinetic factors and the system temperature did not exceed 5°C due 
to the exothermic nature of the reaction. After all the steps, the yield 
obtained for NDIBP was 85.7%, a satisfactory amount considering the 
selected synthetic route. This result was similar to the obtained by 
Zhuge et al. [50] who synthesized the organic nitrate 1,3-bis(hexyloxy)
propan-2-yl (NDHP) confirming that this synthetic route is suitable for 
obtaining organic nitrates.
Regarding the chemical characteristics, NDIBP (Fig. 1b) presented 
C11H23NO5 as molecular formula, molar mass value of 249.16 g/mol and 
the following elemental analysis: C: 52.99%; H: 9.30%; N: 5.62%; and 
O: 32.09%. NDIBP was considered a molecule with simple structure, 
and then its purity and structure were completely confirmed using 
FTIR spectroscopy and 1H and 13C NMR (supporting information). 
Furthermore, it was a viscous liquid with slightly yellow color and 
thermal stability up to 60°C, soluble in chloroform, dichloromethane 
and, ethyl ether and poorly soluble in water and ethanol. Besides 
NDIBP, our group has previous experience with other organic nitrates 
obtained from glycerin with confirmed pharmacological activity such 
as 2-nitrate-1,3-dibuthoxypropan (NDBP), 1,3-bis (hexyloxy) propan-
2-yl nitrate (NDHP), and 2-nitrate-1,3-di(octanoxy)propane [12,51,52] 
corroborating the idea that the use of low cost renewable natural 
sources, such as the glycerin, can be a promising alternative to obtain 
new substances to treat cardiovascular diseases.
PASS prediction indicates NDIBP as a NO donor with vasodilator 
effect
After NDIBP synthesis, PASS was used to predict the spectrum of 
NDIBP biological activities. For this study, we considered only predicted 
activities with probability (Pa) > 0.7. PASS analysis showed 1656 of 
5050 possible biological activities. The prediction of pharmacological 
effects demonstrated that NDIBP presented 167 of 504 possible effects 
(Pa > Pi). However, according to cutoff value of Pa > 0.7, NDIBP showed 
only 29 of 167 predicted pharmacological effects (Table 1).
Among the selected effects, we highlight the highest values of Pa for 
antihypertensive, antianginal, and vasodilator effect (0.973, 0.969, 
and 0.967, respectively). All these effects are in accordance with the 
effects presented by the organic nitrates used in the clinics such as 
GTN, isosorbide mononitrate (ISMN) and ISDN. Those compounds 
develop several hemodynamic actions that are induced by the effect of 
vasodilation of capacitance veins and conductance arteries leading to: 
(i) A reduction in vascular resistance; (ii) decrease in ventricular pre-load 
and left ventricular systolic wall tension; (iii) reduction in myocardial 
O2 consumption, and (iv) increase in subendocardial myocardial blood 
flow which improve the symptoms of several cardiovascular disorders 
such as acute and chronic congestive heart failure, angina pectoris, 
coronary artery disease, and hypertension [53,54]. Therefore, the 
in silico data showed that predicted effects of NDIBP are desirable for a 
drug candidate for the treatment of cardiovascular disorders, including 
hypertension. 
Furthermore, other pharmacological effects were predicted for NDIBP 
(Table 1), including analgesic, spasmolytic, and platelet aggregation 
inhibitor (Pa = 0.944, 0.871, and 0.846, respectively). These findings 
give information and provide support to stimulate the assessment of 
unknown potential effects of NDIBP that can be promising.
To explain the pharmacological effects, 1333 of 4255 possible 
mechanisms of action with Pa > Pi were predicted, but according 
to our cutoff value, only 18 of 1333 were considered. The highest Pa 
values were associated with vasodilator, analgesic, and NO donor (Pa = 
0.967, 0.944, and 0.923, respectively) activities (Table 2). In this study, 
we confirmed the NDIBP’s ability to serve as NO donor, which is the 
main mechanism of action developed by the already known organic 
nitrates [2]. Endogenous NO is considered the most important biological 
signaling molecule involved in regulation of several cardiovascular 
functions, including the control of vascular tone, which directly 
influences in the systemic vascular resistance and the modulation 
of blood pressure [55-57]. Organic nitrates are used when the 
endothelium-dependent vasorelaxation is impaired acting as prodrugs 
able to release the free radical NO from its structure by enzymatic or 
nonenzymatic pathways [58]. Once released, it stimulates the soluble 
guanylyl cyclase (sGC) presented in the vascular smooth muscle cells 
(VSMCs) to induce the formation of cyclic guanosine monophosphate 
(cGMP). The increase in cGMP levels activates the protein kinase G (PKG), 
which promotes the reuptake of cytosolic calcium by sarcoplasmic-
endoplasmic reticulum calcium pump (SERCA), expulsion of calcium 
out of the cell by membrane pumps and sodium/calcium exchanger, 
inhibition of voltage-dependent calcium channels (CaV) and opening 
of calcium-dependent potassium channels (BKCa). All of these events 
induce the reduction of intracellular calcium which impairs the myosin 
light chain kinase (MLCK) to phosphorylate the regulatory myosin light 
chain (rMLC) avoiding the contraction, resulting in VSMC relaxation and 
consequently the modulation of vascular resistance [2,54,59-61]. Our 
PASS analysis indicated NDIBP as a NO donor; therefore, it may be able 
to release NO from its structure and act in the vessels developing the 
vasodilator mechanism mentioned before. 
Other important predicted mechanisms were spasmolytic, cGMP 
phosphodiesterase (PDE) inhibitor and platelet aggregation inhibitor 
(Pa=0.871, 0.850, and 0.846, respectively) (Table 2). We highlight the 
PDE inhibitor mechanism as another way to help in the predicted 
vasodilator effect induced by NDIBP. PDEs are a superfamily of enzymes 
that hydrolyze and inactivate the second messengers 3’,5’-cyclic 
adenosine monophosphate (cAMP) and cGMP [62]. In VSMCs, the cGMP 
levels are controlled by the activity of PDE1 but mainly by PDE5 [63]. 
Normally, the increase in cGMP induced by NO can active the PDE5 
Table 1: Prediction of NDIBP pharmacological effects by PASS software
Predicted pharmacological effect Pa Pi Predicted Pharmacological Effect Pa Pi
Antihypertensive 0.973 0.003 Alzheimer’s disease treatment 0.821 0.004
Antianginal 0.969 0.001 Antidote, cyanide 0.811 0.004
Vasodilator 0.967 0.001 Respiratory analeptic 0.810 0.006
Myocardial infarction treatment 0.948 0.002 Reproductive disfunction treatment 0.784 0.003
Analgesic 0.944 0.004 Miotic 0.774 0.004
Analgesic, non-opioid 0.943 0.004 Erectile dysfunction treatment 0.768 0.003
Vasodilator, coronary 0.914 0.003 Angiogenesis stimulant 0.767 0.003
Osteoarthritis treatment 0.878 0.001 Spasmolytic, urinary 0.761 0.004
Cardiotonic 0.874 0.004 Antiarthritic 0.751 0.009
Myocardial ischemia treatment 0.870 0.003 Analeptic 0.740 0.007
Spasmolytic 0.871 0.004 Anesthetic 0.729 0.004
Rheumatoid arthritis treatment 0.864 0.003 Vasoprotector 0.719 0.006
Antiischemic 0.863 0.004 Vasodilator, peripheral 0.708 0.007
Platelet aggregation inhibitor 0.846 0.004 Neurodegenerative treatment 0.707 0.008
Heart failure treatment 0.830 0.003
Pa: Probability of active, Pi: Probability of inactive
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which initiates a negative feedback mechanism to limit the action of 
cGMP in the vasodilatory cascade [64-66]. In AH, the vascular changes 
can be closely linked to the increased in humoral factors, such as 
angiotensin II [67] and it has been reported that this peptide can raise 
PDE5A protein expression/activity in VSMCs [68].
The use of PDE inhibitors promotes an increase in the vascular signaling of 
NO/cGMP pathway giving support to a higher vasodilator effect [69,70]. 
Several studies demonstrated that inhibition of PDE5 increase 
endothelial function, improve baroreflex sensitivity, and decrease 
blood pressure in experimental models of hypertension [71-74]. In this 
study, NDIBP was also appointed as a PDE inhibitor suggesting that this 
drug can potentiate the vasodilatory cascade induced by the NO release 
through preventing the degradation of cGMP by PDE5. Our organic 
nitrate has the combination of these two mechanisms in one molecule 
and can represent an interesting alternative to treat hypertension due 
to the synergistic effects, which may enhance the hypotensive effects.
PASS software was also able to predict whether NDIBP can induce 
gene expression regulation. Thus, 65 of 96 possible gene expression 
regulation with Pa > Pi were detected, but only 3 of 65 can be considered 
(Pa > 0.7). NDIBP may be an apolipoprotein A1 (APOA1) and HMOX1 
(Heme Oxygenase 1) expression enhancer (Pa = 0.915 and 0.755) and 
also a CASP3 (Caspase 3) expression inhibitor (Pa = 0.752) (Table 3).
Regarding cardiovascular diseases, the most interesting is the APOA1 
expression induced by NDIBP. APOA1 is the main protein component 
in high-density lipoprotein (HDL) particles acting as a mediator in 
the transfer of cholesterol from cells to HDL, an important process 
for the reverse transport of cholesterol to the liver [75,76]. Thus, 
APOA1 is considered as atheroprotective and the risk to develop 
cardiovascular disease is inversely proportional to serum levels of HDL 
and APOA1 [75,77]. Lower levels in HDL due to APOA1 deficiency can 
reduce the atheroprotective potential and facilitate the development of 
atherosclerosis and endothelial dysfunction, important risk factors for 
hypertension [78]. Under our experimental conditions, NDIBP showed 
a predictive ability to enhance the APOA1 expression suggesting 
that this drug can also help to maintain the cardiovascular health by 
reducing the plasmatic cholesterol levels and preventing oxidation and 
aggregation of low-density lipoprotein particles in the vessel wall.
The last aspect of NDIBP biological spectra was related to toxic and 
adverse effects and was predicted 54 of 64 possibilities. Among those, 
only 27 were over Pa value cutoff (Table 4) and the most important 
actions involved skin and eyes irritative effects and hypotension. Other 
toxicity studies were done in the ADMET analysis using the pkCSM 
software. Therefore, NDIBP showed predicted pharmacological effects 
and mechanisms of action that support the investigation of its action on 
the cardiovascular function.
NDIBP induces vasorelaxant effect in superior mesenteric artery
An ex vivo approach using mesenteric arteries rings without functional 
endothelium was used to experimentally confirm the vasodilator effect 
predicted by PASS. The removal of vascular endothelium avoided 
the influence of the endothelium-derived relaxing factors (EDRF). 
Cumulative administration of the glycerin-derived organic nitrate 
NDIBP (10-12-10-4 M) induced a concentration-dependent vasorelaxant 
effect in phenylephrine pre-contracted mesenteric artery rings (Fig. 2).
GTN was used as a positive control once it is a classical organic nitrate 
and as expected, its cumulative addition (10–12–10−4 M) induced a 
concentration-dependent relaxant effect with 112.12±2.66% of ME. 
Although NDIBP presents only one nitrate group in the structure 
its concentration-response curve obtained an expressive ME of 
105.97±3.65% with no statistic significant differences in comparison 
to GTN, which exhibits three groups in its molecule. Any effect was 
not shown in the vessel preparations when just the vehicle was used, 
demonstrating that the cumulative administration of the vehicle was 
unable to induce any significant vasorelaxation. The ME obtained by 
the vehicle in the concentration-response curve was 12.78±2.42%. 
According to this, NDIBP response proves that the theoretical 
predictions are in agreement with the experimental results, validating 
PASS analysis and demonstrating that NDIBP is a vasorelaxant agent. 
Other organic nitrates derived from glycerin such as NDBP and 
NDHP also produced vasorelaxant effect in ex vivo experiments using 
mesenteric arteries rings [12,50,52]. They were considered as NO 
donors developing vasorelaxation through NO release and activation 
of NO-sGC-cGMP-PKG pathway with the participation of some K+ 
channels [12,50,52]. In this study, we suggested by PASS analysis 
(Table 2) that NDIBP may be a NO donor and based on the EDRF 
independent vasorelaxant effect we suggest that NDIBP response 
would occur following the same mechanism of action of the organic 
nitrates mentioned above.
ADMET prediction indicates that NDIBP is a drug-like molecule
One drug is considered promising when it has a fine balance between 
low toxicity, good pharmacological effects (potency and efficacy) and 
ADMET properties [21,25]. Thus, the PK profile is crucial for the drug 
effectiveness. To understand this profile, NDIBP physicochemical 
properties of TPSA, LogP, nHBA, nHBD, and ROTB were predicted with 
the help of pkCSM software.
The physicochemical parameters obtained in this study were used to 
understand and predict NDIBP aspects of ADMET and its drug-like 
nature. Theoretical physicochemical characteristics of NDIBP are 
shown in Table 5 and can be compared with other organic nitrates 
described in the literature [79-81]. All of these pharmacological 
descriptors are related to the passive transport across membranes, that 
Table 2: NDIBP’s mechanisms of action predicted by PASS software
Predicted mechanism of action Pa Pi Predicted mechanism of action Pa Pi
Vasodilator 0.967 0.001 Acrocylindropepsin inhibitor 0.852 0.007
Analgesic 0.944 0.004 Chymosin inhibitor 0.852 0.007
Nitric oxide donor 0.923 0.000 Platelet aggregation inhibitor 0.846 0.004
APOA1 expression enhancer 0.915 0.003 Cutinase inhibitor 0.820 0.004
Vasodilator, coronary 0.914 0.003 Miotic 0.774 0.004
Cardiotonic 0.874 0.004 Angiogenesis stimulant 0.767 0.003
Spasmolytic 0.871 0.004 Polyporopepsin inhibitor 0.777 0.015
Cyclic GMP PDE inhibitor 0.850 0.001 Fragilysin inhibitor 0.734 0.010
Saccharopepsin inhibitor 0.852 0.007 Vasodilator, peripheral 0.708 0.007
Pa: Probability of active, Pi: Probability of inactive, APOA1: Apolipoprotein A1, GMP: Guanosine monophosphate, PDE: Phosphodiesterase
Table 3: Prediction of NDIBP gene expression regulation by PASS 
software
Predicted gene expression regulation Pa Pi
APOA1 expression enhancer 0.915 0.003
HMOX1 expression enhancer 0.755 0.012
CASP3 expression inhibitor 0.752 0.013
Pa: Probability of active, Pi: Probability of inactive, APOA1: Apolipoprotein A1, 
HMOX1: Heme oxygenase 1, CASP3: Caspase3
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is, permeability, revealing aspects of membrane permeation rate, drug 
absorption, and bioavailability of the compound [82-88].
According to the prediction, NDIBP presented the lowest TPSA value 
when compared to other organic nitrates used in the clinic such as GTN 
and ISDN suggesting a probable greater facility to cross cell membranes 
(Table 5). In general, a higher logP value indicates a high lipophilicity 
and consequently a good drug permeability across cell membranes, 
but compounds with logP > 5 are poorly absorbed [46,88]. According 
to PASS analysis, NDIBP was within the recommended range of the 
optimum region of lipophilicity with logP between -2 and 5 [89,90] and 
also presented the highest logP value in comparison to GTN, ISMN, and 
ISDN, indicating probable higher lipophilicity (Table 5). The higher is 
the number of ROTB (nROTB) the greater is the molecule flexibility, 
leading to negative effects on the compound permeability [82]. NDIBP 
showed the highest predicted value of nROTB compared to the other 
mentioned organic nitrates (Table 5). Although NDIBP presented a 
high nROTB, it is still within the range established by Verber et al. [82] 
(nROTB ≤ 10) to develop a good permeation and oral bioavailability. 
Thus, according to pkCSM predictions and when all the physicochemical 
parameters are associated and compared, NDIBP probably results in a 
better permeation across cell membranes and molecule flexibility than 
the other mentioned organic nitrates, which can influence to it develop 
a better drug absorption and bioavailability.
Next, NDIBP molecular descriptors were analyzed through the 
Lipinski’s RO5, which can estimate the likeliness of the molecule to 
act as a drug [46] (Table 5). This analysis is important for theoretical 
prediction of oral bioavailability profile and its based on five conditions: 
(1) nHBA less than or equal to 10; (2) nHBD less than or equal to 5; 
(3) MW less than or equal to 500 g/mol; (4) logP less than or equal to 
5, and (5) TPSA less than or equal to 140 Å2 [46,91,92]. When more 
than one of these rules are violated it means that the molecule may 
has problems with absorption or permeability and consequently with 
bioavailability [37,93].
The data obtained in this study (Table 5) showed that NDIBP 
satisfied all the rules established by Lipinski suggesting that it may 
have a high tendency to penetrate into cell membrane and develop a 
good theoretical oral bioavailability. In addition, according to Veber 
et al. [82], compounds with nROTB less than or equal to 10 present a 
high probability of good oral bioavailability. As shown previously, the 
value of nROTB obtained for NDIBP is within the threshold established 
and corresponds to one more aspect to suggest the high probability of 
being used orally. As shown, NDIBP presents all the eligible aspects to 
meet the drug-likeness criteria.
It is important to highlight that the appreciation of ADMET properties 
throughout the drug discovery process has become relevant to 
unravel compounds with poor ADME aspects at the earlier stage of 
Table 5: Theoretical analysis of NDIBP physicochemical properties obtained by pkCSM software
Compound Physicochemical properties
MW (g/mol) TPSA (Å2) LogP nHBA nHBD nROTB RO5 violations
NDIBP 249.16 102 2 5 0 10 0
GTN 227.09 165 1.6 9 0 5 0
ISMN 191.14 93.7 -0.4 6 1 1 0
ISDN 236.14 129 1.3 8 0 2 0
MW: Molecular weight, TPSA: Topological polar surface area, LogP: Partition coefficient, nHBA: Number of hydrogen bond acceptor, nHBD: Number of hydrogen bond 
donors, nROTB: Number of rotable bonds, RO5: Rule of five
Table 4: Prediction of NDIBP toxic and adverse effects by PASS software
Predicted toxic/adverse effects Pa Pi Predicted toxic/adverse effects Pa Pi
Skin irritative effect 0.962 0.002 Neurotoxic 0.855 0.010
Skin irritation, weak 0.946 0.002 Carcinogenic, rat, female 0.844 0.003
Eye irritation, weak 0.944 0.002 Carcinogenic, rat 0.842 0.004
Hypotension 0.927 0.007 Cardiotoxic 0.840 0.015
Skin irritation, high 0.921 0.003 Dermatitis 0.836 0.014
Irritation 0.904 0.005 Allergic reaction 0.810 0.016
Ocular toxicity 0.894 0.008 Carcinogenic 0.802 0.010
Nephrotoxic 0.889 0.008 Eye irritation, high 0.793 0.005
Hepatotoxic 0.881 0.012 Embryotoxic 0.786 0.012
Carcinogenic, rat, male 0.866 0.003 Teratogen 0.771 0.013
Anemia 0.870 0.008 Toxic 0.782 0.026
Endocrine disruptor 0.869 0.008 Mutagenic 0.749 0.009
Hematotoxic 0.870 0.014 Anaphylaxis 0.745 0.016
Reproductive dysfunction 0.865 0.013
Pa: Probability of active, Pi: Probability of inactive
Fig. 2: Vasorelaxation effect of NDIBP, GTN, or vehicle. The panel 
shows the NDIBP, GTN, or vehicle cumulative concentration-response 
curves (10-12–10-4 M) on mesenteric arteries isolated from rats (n=6) 
pre-contracted with phenylephrine (1 μM). Log [M] corresponds to 
the different concentrations of vehicle, NDIBP and GTN respectively. 
*p<0.05 statistically different in relation to the maximum effect of 
vehicle control. One-way analysis of variance followed by Tukey test
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the drug development and thus reduce the number of compounds 
that fail in clinical trials [94-96]. Predicted NDIBP ADMET aspects are 
demonstrated in Table 6.
The absorption of drugs proposed to be used orally depends on their 
ability to cross the walls of gastrointestinal tract (GTI) [97]. Due to 
this, NDIBP absorption profile was based on Caco-2 permeability and 
HIA. For this predictive model, a compound may have a high Caco-2 
permeability when Papp > 0.90 and a good intestinal absorbance 
when the value is higher than 30% [25]. According to the results, 
NDIBP presented both a high Caco-2 permeability and high intestinal 
absorption (Table 6). Caco-2 cells are extracted from the human 
epithelial colorectal adenocarcinoma being widely used once these 
cells can mimic the gastrointestinal epithelium representing a 
validated assay system for oral absorption studies [88,98,99] and 
HIA is the sum of bioavailability and absorption evaluated from the 
cumulative excretion in bile, urine, and feces [100]. Therefore, the data 
suggested that NDIBP may probably cross the membrane of GTI and 
develop a good oral absorption corroborating the analysis based on 
Lipinski’s RO5.
Skin permeability was also predicted and NDIBP demonstrated a 
relatively low skin permeability as indicated by the value of logKp 
>–2.5 [25]. This parameter suggested that a topical administration 
could not be a good alternative for NDIBP absorption. The drug 
absorption can also be influenced by the presence of efflux proteins 
in cell membrane. One of this protein is Pgp an ATP-binding cassette 
transporter that pumps drug out from the intestinal cell [101-104]. The 
predicted result showed that NDIBP is a non-substrate as well as a non-
inhibitor of Pgp (Table 6). Due to not being a substrate, it means that 
Pgp may not recognize the organic nitrate and may not cause its cell 
efflux and being a non-inhibitor the NDIBP shall not make interactions 
with Pgp in any way, so its function to promote xenobiotics efflux will 
be not blocked.
The distribution of NDIBP from the systemic circulation to extravascular 
tissues was assessed based on the VDss and BBB permeability (Table 6). 
VDss represent the volume of body fluid that a total dose of a drug 
needs to be distributed to obtain the same concentration presented 
in blood plasma [105], being an important indicator to determine 
dosage prescription of a compound [27]. According pkCSM predictive 
model, VDss is considered low when it is <0.71 L/kg and high when 
>2.81 L/kg [25]. VDss value of NDIBP was below 0.71 reflecting a low 
distribution to extravascular tissues. Most of the pharmacological 
targets of the drugs are not presented at the vasculature and the 
access to them relies on organ distribution [106]. However, most of the 
activities predicted for organic nitrates are related to vascular action, 
justifying the low value of distribution of NDIBP.
Another important aspect is the BBB permeability since this 
physiological barrier composed by endothelial cells regulates the 
passage of compounds from the blood to the central nervous system 
(CNS), developing a protective property [97]. For the pkCSM model, a 
compound with logBB > 0.3 can readily cross the BBB while compounds 
with logBB < −1 have difficulty to be distributed to the brain [25]. 
NDIBP presented an intermediate value of BBB permeability suggesting 
that it may have some distribution into the brain. The liposolubility of 
compound may contribute to cross this barrier and probably develop 
actions at central nervous system level.
Evaluation of first pass metabolism in the liver characteristics depends 
on interaction with the several microsomal enzymes known as 
cytochrome P450 (CYP450) [97]. These enzymes are mostly located in 
the liver and responsible for the majority of drug first-pass metabolism 
highlighting CYP3A4 that performs almost 50% of the metabolism 
of xenobiotics in humans [107,108]. ADMET prediction showed that 
NDIBP is a non-substrate of CYP2D6 and CYP3A4 isoforms as well as 
a non-inhibitor of CYP2C9, CYP2C19, CYP2D6, and CYP3A4 isoforms 
(Table 6). The data suggested that NDIBP may not be metabolized by the 
selected CYP isoforms being chemically inert once it is not able to active 
the enzymes as a substrate and at the same time it may not promote 
the loss of function of CYP isoforms and interferes in the metabolism of 
other drugs because it was not considered an inhibitor.
Molecules with high levels of metabolization by cytochrome P450 
have reduced oral bioavailability and plasma half-life [109]. Based 
on this, NDIBP probably presents a good bioavailability and length of 
time in the plasma once this nitrate does not pass through first-pass 
metabolism by CYP isoforms.
Excretion is another important PK parameter that describes the 
process to remove intact drug molecules or its metabolites from the 
body determining the period of time the drug remains in the organism 
as well the volume of distribution [95,106,107]. This process was 
analyzed based on total clearance and a categorical classification of 
NDIBP as a renal OCT2 substrate (Table 6). There is not a limited range 
of total clearance, the higher the value, the faster will be the excretion 
process [25]. The NDIBP value of total clearance was just an estimative 
and with this, the rate of excretion can be predicted. PASS prediction 
also showed that NDIBP may not be an OCT2 substrate. OCT2 is a renal 
Table 6: Theoretical analysis of NDIBP ADMET properties obtained by pkCSM software
ADMET properties Model name Predicted result Unit Interpretation
GI Absorption Caco-2 permeability 0.92 Numeric (log Papp in 10-6 cm/s) High: > 0.90
Human intestinal absorption 95.02 Numeric (% Absorbed) Poor absorbed: < 30%
Skin permeability -2.28 Numeric (log Kp) Low permeability: > -2.5
P-glycoprotein substrate No Categorical (Yes/No) Yes/No
P-glycoprotein I inhibitor No Categorical (Yes/No) Yes/No
P-glycoprotein II inhibitor No Categorical (Yes/No) Yes/No
Distribution Volume of distribution -0.28 Numeric (log L/kg) Low: < 0.71; High: > 2.81 
Blood brain barrier permeability -0.71 Numeric (logBB) Low: < −1; High: > 0.30
Metabolism Substrate CYP2D6 No Categorical (Yes/No) Yes/No
Substrate CYP3A4 No Categorical (Yes/No) Yes/No
Inhibitor CYP2C9 No Categorical (Yes/No) Yes/No
Inhibitor CYP2C19 No Categorical (Yes/No) Yes/No
Inhibitor CYP2D6 No Categorical (Yes/No) Yes/No
Inhibitor CYP3A4 No Categorical (Yes/No) Yes/No
Excretion Total clearance 0.67 Numeric (log ml/min/kg) Log ml/min/kg
Renal OCT2 Substrate No Categorical (Yes/No) Yes/No
Toxicity AMES toxicity No Categorical (Yes/No) Yes/No
Pred- hERG No Categorical (Yes/No) Yes/No
Hepatotoxicity No Categorical (Yes/No) Yes/No
Pred-skin Yes Categorical (Yes/No) Yes/No
OCT2: Organic cation transporter 2, hERG: Human ether-a-go-go-related gene, Pred-skin: Skin sensitization prediction
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uptake transporter responsible for renal clearance of the drugs [110]. 
The ability of the compound to binding to this protein is an indication 
of its clearance which is an important aspect to determine the dosing 
rate to achieve a steady-state on plasma [111]. According to the results, 
NDIBP is unable to interact and bind to this transporter and may not be 
excreted by this way.
Drug toxicity is the most important causes of impairment of the 
process of drug discovery and development [112]. Due to this, NDIBP-
induced toxicity was also evaluated by pkCSM (Table 6). The genetic 
toxicity screening to identify NDIBP potential to be mutagenic or non-
mutagenic was assessed by the AMES mutagenic test. Compounds that 
present a positive result in AMES test may cause mutagenicity [25,113]. 
According to the analysis, NDIBP showed a negative result and probably 
is not a mutagenic compound and therefore may not act as a carcinogen. 
The cardiotoxicity of NDIBP was evaluated by testing whether this 
organic nitrate could be a hERG I and II inhibitor. hERG channels play 
an important role in the cardiac repolarization [114-116] and the hERG 
current inhibition is the most likely mechanism involved in the drug-
induced QT interval prolongation and severe cardiac arrhythmias being 
an important reason of drug failure in preclinical studies [25,117]. 
NDIBP did not show any positive results for inhibition of neither hERG 
I nor hERG II, reflecting the cardioprotective nature of this organic 
nitrate.
Another important concern in drug development is hepatotoxicity, 
one of the main reasons to remove medications post-market [118]. 
Drug-induced liver injury can lead to acute liver failure and even 
death [119,120]. In silico analysis showed that NDIBP was not able to 
cause disruption in the normal liver function and therefore, may not 
be considered as a hepatotoxic compound (Table 6). However, NDIBP 
developed a predicted skin sensitization that was also showed in 
PASS analysis. Skin sensitization is a potential adverse effect for drugs 
that are applied dermally [25]. The NDIBP information about its skin 
permeability in addition to skin sensitization corroborated the idea that 
the topical administration of this organic nitrate could be an inadequate 
way to obtain the pharmacological effect due to its poor absorption at 
the skin and the development of this undesirable adverse effect.
CONCLUSION
In summary, our study described NDIBP as a drug candidate with 
vasorelaxant activity. In silico analysis provided relevant data about 
its biological activities and PK aspects. PASS software was successfully 
applied to predict the organic nitrate biological spectra directing 
the study to the most correct experimental protocol to test the 
pharmacological effect related to cardiovascular aspects, avoiding waste 
of time and cost of chemicals. This study emphasizes that vasodilator 
effect was not only predicted but also validated in ex vivo experiments 
that allowed to propose the NDIBP as a potential vasorelaxant that 
could be investigated in the treatment of hypertension. Furthermore, 
pkCSM analysis suggested that NDIBP possess good oral absorption and 
bioavailability, suggesting that this organic nitrate can be a promising 
hit. All these computational data qualify the NDIBP for further in vitro 
and in vivo studies to understand the PK aspects more deeply and to 




Valdir Braga was responsible for the design of the study, funding, and 
supervision; Airlla Cavalcanti and Patrícia Rocha contributed with 
methodology, formal analysis, writing—original draft preparation; 
Isadora Luna carried out the in silico methodology; Maria Cláudia 
Brandão and Emmely Trindade performed the synthesis of the 
compound; Geovani Pereira contributed with the writing–review and 
editing; Petrônio Athayde-Filho, Eugene Muratov, Barkat Khan, and 
Marcus Scotti provided to the study the access to crucial research 
components (reagents, equipment, and computational software), 
expertise, and feedback. All authors have read and agreed to the 
published version of the manuscript.
CONFLICTS OF INTEREST
The authors declare that they have no conflict of interest.
AUTHORS FUNDING
This work was supported by grants from the Conselho Nacional de 
Desenvolvimento Científico e Tecnológico - CNPq (ID: 472133/2013-
6; 304772/2014-3; 429767/2016-1, VAB), Coordenação de 
Aperfeiçoamento de Pessoal de Nível Superior-Capes (Capes) and 
Paraiba State Research Foundation (FAPESQ, ID: 007/2019 FAPESQ-
PB-MCT/CNPq). The funding sources were not involved in study design; 
in the collection, analysis and interpretation of data; in the writing of 
the report or in the decision to submit the article for publication.
REFERENCES
1. Egan BM, Kjeldsen SE, Grassi G, Esler M, Mancia G. The global 
burden of hypertension exceeds 1.4 billion people: Should a systolic 
blood pressure target below 130 become the universal standard? J 
Hypertens 2019;37:1148-53.
2. Balarini CM, Cruz JC, Alves JL, França-Silva MS, Braga VA. 
Developing New Organic Nitrates for Treating Hypertension. 
Cambridge, Massachusetts: Academic Press; 2017. p. 243-262.
3. Pinheiro LC, Tanus-Santos JE, Castro MM. The potential of 
stimulating nitric oxide formation in the treatment of hypertension. 
Expert Opin Ther Targets 2017;21:543-56.
4. Tousoulis D, Simopoulou C, Papageorgiou N, Oikonomou E, 
Hatzis G, Siasos G, et al. Endothelial dysfunction in conduit arteries 
and in microcirculation: Novel therapeutic approaches. Pharmacol 
Ther 2014;144:253-67.
5. Veerasamy M, Bagnall A, Neely D, Allen J, Sinclair H, Kunadian V. 
Endothelial dysfunction and coronary artery disease: A state of the art 
review. Cardiol Rev 2015;23:119-29.
6. Kang N, Lee JH, Lee WW, Ko JY, Kim EA, Kim JS, et al. Gallic 
acid isolated from Spirogyra sp. improves cardiovascular disease 
through a vasorelaxant and antihypertensive effect. Environ Toxicol 
Pharmacol 2015;39:764-72.
7. Förstermann U, Sessa WC. Nitric oxide synthases: Regulation and 
function. Eur Heart J 2012;33:829a-37d.
8. Münzel T, Daiber A, Gori T. Nitrate therapy: New aspects concerning 
molecular action and tolerance. Circulation 2011;123:2132-44.
9. Katsumi H, Nishikawa M, Hashida M. Development of nitric oxide 
donors for the treatment of cardiovascular diseases. Cardiovasc 
Hematol Agents Med Chem 2007;5:204-8.
10. Levine AB, Punihaole D, Levine TB. Characterization of the role of 
nitric oxide and its clinical applications. Cardiology 2012;122:55-68.
11. Yeo TW, Lampah DA, Gitawati R, Tjitra E, Ke-Nangalem E, 
Mcneil YR, et al. Impaired nitric oxide bioavailability and l-arginine 
reversible endothelial dysfunction in adults with falciparum malaria. 
J Exp Med 2007;204:2693-704.
12. França-Silva MS, Luciano MN, Ribeiro TP, Silva JS, Santos AF, 
França KC, et al. The 2-nitrate-1,3-dibuthoxypropan, a new nitric 
oxide donor, induces vasorelaxation in mesenteric arteries of the rat. 
Eur J Pharmacol 2012;690:170-5.
13. Münzel T, Daiber A, Mülsch A. Explaining the phenomenon of 
nitrate tolerance. Circ Res 2005;97:618-28.
14. Omar SA, Artime E, Webb AJ. A comparison of organic and inorganic 
nitrates/nitrites. Nitric Oxide 2012;26:229-40.
15.	 Klemenska	E,	Beręsewicz	A.	Bioactivation	of	organic	nitrates	and	the	
mechanism of nitrate tolerance. Cardiol J 2009;16:11-9.
16. Poroikov VV, Filimonov DA, Ihlenfeldt W, Gloriozova TA, 
Lagunin AA, Borodina Y, et al. PASS biological activity spectrum 
predictions in the enhanced open NCI database browser. J Chem Inf 
Comput Sci 2003;43:228-36.
17. Lagunin AA, Dubovskaja VI, Rudik AV, Pogodin PV, Druzhilovskiy 
1H NMR spectrum (400 MHZ, CDCl3) of NDIBP; Fig. 3: 13C NMR spectrum
 (50 MHZ, CDCl3) of NDIBP.
Additional figures illustrating the FTIR spectroscopy and 1H and 13C 
NMR spectra of NDIBP. Fig. S1: FTIR (ATR) spectrum of NDIBP; Fig. S2: 
132
Asian J Pharm Clin Res, Vol 14, Issue 4, 2021, 124-134
 Cavalcanti et al.
DS, Gloriozova T, et al. CLC-Pred: A freely available web-service 
for in silico prediction of human cell line cytotoxicity for drug-like 
compounds. PLoS One 2018;13:e0191838.
18. Lagunin A, Stepanchikova A, Filimonov D, Poroikov V. PASS: 
Prediction of activity spectra for biologically active substances. 
Bioinformatics 2000;16:747-8.
19. Saffari-Chaleshtori J, Heidari-Soreshjani E, Asadi-Samani M. 
Computational study of quercetin effect on pre-apoptotic factors of 
Bad, Bak and Bim. J Herbmed Pharmacol 2016;2:61-6.
20. Chinnasamy P, Arumugam R. In silico prediction of anticarcinogenic 
bioactives traditional anti-inflammatory plants used by tribal healers 
in Sathyamangalam wildlife Sactuary, India. Egypt J Basic Appl Sci 
2018;5:265-79.
21. Moroy G, Martiny VY, Vayer P, Villoutreix BO, Miteva MA. Toward 
in silico structure-based ADMET prediction in drug discovery. Drug 
Discov Today 2012;2:44-55.
22. Aniyery RB, Gupta A, Singh P, Khatri C, Pathak A. Synthesis, 
characterization, biological activities and computational anticancer 
study of dibutylbis [(2-isopropyl-5-ethylcyclohexyl) oxy] stannane. J 
Chem Pharm Sci 2015;8:957-63.
23. Salgueiro AC, Folmer V, Rosa HS, Costa MT, Boligon AA, Paula FR, 
et al. In vitro and in silico antioxidant and toxicological activities of 
Achyrocline satureioides. J Ethnopharmacol 2016;194:6-14.
24. ECHA-European Chemicals Agency. Non-animal Approaches 
Current Status of Regulatory Applicability under the REACH, CLP 
and Biocidal Products Regulations. Available from: https://www.
echa.europa.eu/support/registration/how-to-avoid-unnecessary-
testing-on-animals. [Last accessed on 2020 April 05].
25. Pires DE, Blundell TL, Ascher DB. pkCSM: Predicting small-
molecule pharmacokinetic and toxicity properties using graph-based 
signatures. J Med Chem 2015;58:4066-72.
26. Sasikala RP, Meena KS. Identification of biological activities of 
Abutilon indicum fruit by in silico and in vitro approach. Karbala Int 
J Mod Sci 2018;4:287-96.
27. Fatima S, Gupta P, Sharma A, Agarwal SM. ADMET profiling of 
geographically diverse phytochemical using chemoinformatic tools. 
Future Med Chem 2020;12:69-87.
28. Fisher J. Organic Nitro Series, Recent Advanced in Synthesis and 
Chemistry. New York: VCH; 1990.
29. Olah GA, Ripudaman M, Narang, SC. Nitration, Methods and 
Mechanism: Across Conventional Lines. New York: VCH; 1989. p. 
975-9.
30. Parasuraman S. Prediction of activity spectra for substances. J 
Pharmacol Pharmacother 2011;2:52-3.
31. Filimonov DA, Lagunin AA, Gloriozova TA, Rudik AV, 
Druzhilovskii DS, Pogodin P, et al. Prediction of the biological 
activity spectra of organic compounds using the PASS online web 
resource. Chem Heterocycl Comp 2014;50:444-57.
32. Kurashov EA, Fedorova EV, Krylova JV, Mitrukova GG. Assessment 
of the potential biological activity of low molecular weight 
metabolites of freshwater macrophytes with QSAR. Scientifica 
2016;2016:1-9.
33. Jamkhande PG, Wattamwar AS, Pekamwar SS, Chandaw PG. 
Antioxidant, antimicrobial activity and in silico PASS prediction of 
Annona reticulata Linn. Root extract. Beni-Suef Univ J Basic Appl 
Sci 2014;3:140-8.
34. Anand A, Sharma N, Khurana N. Prediction of activity spectra of 
substances assisted prediction of biological activity spectra of 
potential anti-Alzheimer’s phytoconstituents. Asian J Pharm Clin Res 
2017;10:13-21.
35.	 Zykova	SS,	Igidov	NM,	Кiselev	MA,	Boichuk	SV,	Galembikova	AR,	
Zagulova DV. Experimental Study on the Development of Anticancer 
Agents Based on Pyrrole Containing Heterocycles. Vol. 18. Health 
and Education in the 21st Century 2016. p. 121-7.
36. Pogodin PV, Lagunin AA, Rudik AV, Filimonov DA, 
Druzhilovskiy DS, Nicklaus MC, et al. How to achieve better results 
using PASS-based virtual screening: Case study for kinase inhibitors. 
Front Chem 2018;6:1-14.
37. Ariffin A, Rahman NA, Yehye WA, Alhadi AA, Kadir FA. PASS-
assisted design, synthesis and antioxidant evaluation of new butylated 
hydroxytoluene derivatives. Eur J Med Chem 2014;87:564-77.
38. Filimonov D, Poroikov V, Borodina Y, Gloriozova, T. Chemical 
similarity assessment through multilevel neighborhoods of atoms: 
Definition and comparison with the other descriptors. J Chem Inf 
Comput Sci 1999;39:666-70.
39. Stepanchikova AV, Lagunin AA, Filimonov DA, Poroikov VV. 
Prediction of biological activity spectra for substances: Evaluation 
on the diverse sets of drug-like structures. Curr Med Chem 
2003;10:225-33.
40. Filimonov DA, Poroikov VV. Prediction of biological activity spectra 
for organic compounds. Russ Chem J 2006;2:66.
41. Filimonov DA, Poroikov VV. Probabilistic approaches in activity 
prediction. In: Varnek A, Tropsha A, editor. Chemoinformatics 
Approaches to Virtual Screening. Cambridge: RSC Publishing; 2008. 
p. 182-216.
42. Goel RK, Lagunin A, Singh D, Poroikov V. PASS-Assisted 
exploration of new therapeutic potential of natural products. Med 
Chem Res 2011;20:1509-14.
43. Khurana N, Ishar MP, Gajbhiye A, Goel RK. PASS assisted 
prediction and pharmacological evaluation of novel nicotinic analogs 
for nootropic activity in mice. Eur J Pharmacol 2011;662:22-30.
44. Munhoz FC, Potje SR, Pereira AC, Daruge MG, Silva RS, 
Bendhack LM, et al. Hypotensive and vasorelaxing effects of the new 
NO-donor [Ru(terpy)(bdq)NO+]3+ in spontaneously hypertensive 
rats. Nitric Oxide 2012;26:111-7.
45. Mendes-Júnior LG, Guimarães DD, Gadelha DD, Diniz TF, 
Brandão MC, Athayde-Filho PF, et al. The new nitric oxide donor 
cyclo-hexane nitrate induces vasorelaxation, hypotension, and 
antihypertensive effects via NO/cGMP/PKG pathway. Front Physiol 
2015;31:243.
46. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental 
and computational approaches to estimate solubility and permeability 
in drug discovery and development settings. Adv Drug Deliv Rev 
1997;23:3-25.
47. Han Y, Zhangb J, Hu C. A systematic toxicity evaluation of 
cephalosporins via transcriptomics in zebrafish and in silico ADMET 
studies. Food Chem Toxicol 2018;116:264-71.
48. Shen J, Zhao Y, Chen G, Yuan Q. Investigation of nitration process 
of iso-octanol with mixed acid in a microreactor. Chin J Chem Eng 
2009;17:412-8.
49. Suppes GJ, Dasari AM. Synthesis and evaluation of alkyl nitrates 
from triglycerides as cetane improvers. Ind Eng Chem Res 
2003;42:5042-53.
50. Zhuge Z, Paulo LL, Jahandideh A, Brandão MC, Athayde-Filho PR, 
Lundberg JO, et al. Synthesis and characterization of a novel organic 
nitrate NDHP: Role of xanthine oxidoreductase-mediated nitric oxide 
formation. Redox Biol 2017;13:163-9.
51. Porpino SK, Travassos RA, Gadelha DD, Balarini CM, Cruz JC, 
Santos AF, et al. Developing new organic nitrates for treating 
hypertension: A review. J Hypertens 2016;5:232.
52. Paulo LL, Cruz JC, Zhuge Z, Carvalho-Galvão A, Brandão MC, 
Diniz TF, et al. The novel organic mononitrate NDHP attenuates 
hypertension and endothelial dysfunction in hypertensive rats. Redox 
Biol 2018;15:182-91.
53. Daiber A, Münzel T. Organic nitrate therapy, nitrate tolerance, and 
nitrate-induced endothelial dysfunction: Emphasis on redox biology 
and oxidative stress. Antioxid Redox Sign 2015;23:899-942.
54. Divakaran S, Loscalzo J. The role of nitroglycerin and other 
nitrogen oxides in cardiovascular therapeutics. J Am Coll Cardiol 
2017;70:2393-410.
55. Maeda S, Tanabe T, Otsuki T, Sugawara J, Iemitsu M, Miyauchi T, 
et al. Moderate regular exercise increases basal production of nitric 
oxide in elderely women. Hypertension Res 2004;27:947-53.
56. Shapoval LN. Nitric oxide: Involvement in the nervous control of 
cardiovascular function. Neurophysiol 2004;36:466-78.
57. Bonaventura D, Lima RG, Vercesi JA, Silva RS, Bendhack LM. 
Comparison of the mechanisms underlying the relaxation induced by 
two nitric oxide donors: Sodium nitroprusside and a new ruthenium 
complex. Vascul Pharmacol 2007;46:215-22.
58. Mayer B, Beretta M. The enigma of nitroglycerin bioactivation 
and nitrate tolerance: News, views and troubles. Br J Pharmacol 
2008;155:170-84.
59. Zhao Y, Vanhoutte PM, Leung SW. Vascular nitric oxide: Beyond 
eNOS. J Pharmacol Sci 2015;129:83-94.
60. Follmann M, Griebenow N, Hahn MG, Hartung I, Mais FJ, 
Mittendorf J, et al. The chemistry and biology of soluble 
guanylate cyclase stimulators and activators. Angew Chem Int Ed 
2013;52:9442-62.
61. Mitchell JA, Ali F, Bailey F, Moreno L, Harrington LS. Role of 
nitric oxide and prostacyclin as vasoactive hormones released by the 
endothelium. Exp Physiol 2008;93:141-7.
62. Keravis T, Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) 
isozymes as targets of the intracellular signalling network: Benefits 
of PDE inhibitors in various diseases and perspectives for future 
133
Asian J Pharm Clin Res, Vol 14, Issue 4, 2021, 124-134
 Cavalcanti et al.
therapeutic developments. Br J Pharmacol 2012;165:1288-305.
63. Rybalkin SD, Rybalkina IG, Shimizu-Albergine M, Tang XB, 
Beavo JA. PDE5 is converted to an activated state upon cGMP 
binding to the GAF A domain. EMBO J 2003a;22:469-78.
64. Rybalkin SD, Yan C, Bornfeldt KE, Beavo JA. Cyclic GMP 
phosphodiesterases and regulation of smooth muscle function. Cir 
Res 2003b;93:280-91.
65. Mullershausen F, Friebe A, Feil R, Thompson WJ, Hofmann F, 
Koesling D. Direct activation of PDE5 by cGMP: Long-term effects 
within NO/ cGMP signaling. J Cell Biol 2003;160:719-27.
66. Mullershausen F, Russwurm M, Koesling D, Friebe A. In vivo 
reconstitution of the negative feedback in nitric oxide/cGMP 
signaling: Role of phosphodiesterase Type 5 phosphorylation. Mol 
Biol Cell 2004;15:4023-30.
67. Touyz RM. Recent advances in intracellular signalling in 
hypertension. Curr Opin Nephrol Hypertens 2003;12:165-74.
68. Kim D, Aizawab T, Weic H, Pic X, Rybalkind SD, Berkc BC, 
et al. Angiotensin II increases phosphodiesterase 5A expression in 
vascular smooth muscle cells: A mechanism by which angiotensin II 
antagonizes cGMP signaling. J Mol Cell Cardiol 2005;38:175-84.
69. Palit V, Eardley I. An update on new oral PDE5 inhibitors for the 
treatment of erectile dysfunction. Nat Rev Urol 2010;7:603-9.
70. Balarini CM, Leal MA, Gomes IB, Pereira TM, Gava AL, 
Meyrelles SS, et al. Sildenafil restores endothelial function in the 
apolipoprotein E knockout mouse. J Transl Med 2013;11:3.
71. Cavalcanti CO, Alves RR, Oliveira AL, Cruz JC, França-Silva MS, 
Braga VA, et al. Inhibition of PDE5 restores depressed baroreflex 
sensitivity in renovascular hypertensive rats. Front Physiol 
2016;7:1-9.
72. Dias AT, Cintra A, Frossard JC, Palomino Z, Casarini DE, Gomes IB, 
et al. Inhibition of phosphodiesterase 5 restores endothelial function 
in renovascular hypertension. J Transl Med 2014;12:250.
73. Thieme M, Sivritas SH, Mergia E, Potthoff SA, Yang G, Hering L, 
et al. Phosphodiesterase 5 inhibition ameliorates angiotensin II-
dependent hypertension and renal vascular dysfunction. Am J 
Physiol-Renal 2017;312:474-81.
74. Ghiadoni L, Versari D, Taddei S. Phosphodiesterase 5 inhibition in 
essential hypertension. Cur Hypert Rep 2008;10:52-7.
75. Chistiakov DA, Orekhov AN, Bobryshev YV. ApoA1 and ApoA1-
specific self-antibodies in cardiovascular disease. Lab Investig 
2016;96:708-18.
76. Carnicer R, Navarro MA, Arbonés-Mainar JM, Arnal C, 
Surra JC, Acín S, et al. Genetically based hypertension generated 
through interaction of mild hypoalphalipoproteinemia and mild 
hyperhomocysteinemia. J Hypertens 2007;25:8.
77. Gordon DJ, Rifkind BM. High-density lipoprotein the clinical 
implications of recent studies. N Engl J Med 1989;321:1311-6.
78. Nayak P, Panda S, Thatoi PK, Rattan R, Mohapatra S, Mishra PK. 
Evaluation of lipid profile and apolipoproteins in essential 
hypertensive patients. J Clin Diagn Res 2016;10:1-4.
79. National Center for Biotechnology Information. PubChem Data-
base. Nitroglycerin CID=4510; 2020.
80. National Center for Biotechnology Information. PubChem Data-
base. Isosorbide Mononitrate CID=27661; 2020.
81. National Center for Biotechnology Information. PubChem Data-
base. Isosorbide Dinitrate CID=6883; 2020.
82. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. 
Molecular properties that influence the oral bioavailability of drug 
candidates. J Med Chem 2002;45:2615-23.
83.	 Veselinović	 JB,	 Kocić	 GM,	 Pavic	 A,	 Nikodinovic-Runic	 J,	
Senerovic	L,	Nikolić	GM	et	al.	Selected	4-phenyl	hydroxycoumarins:	
In vitro cytotoxicity, teratogenic effect on zebrafish (Danio 
rerio) embryos and molecular docking study. Chem Biol Interact 
2015;231:10.
84. Stenberg P, Norinder U, Luthman K, Artursson P. Experimental and 
computational screening models for the prediction of intestinal drug 
absorption. J Med Chem 2001;44:1927-37.
85. Van der Waterbeemd H, Kansy M. Hydrogen-bonding capacity and 
brain penetration. CHIMIA 1992;46:299-303.
86. Ertl P, Rohde B, Selzer P. Fast calculation of molecular polar surface 
area as a sum of fragment-based contributions and its application to the 
prediction of drug transport properties. J Med Chem 2000;43:3714-7.
87. Navia MA, Chaturvedi PR. Design principles for orally bioavailable 
drugs. Drug Discov Today 1996;1:179-89.
88. Ferreira SB, Dantas TB, Silva DF, Ferreira PB, Melo TR, Lima EO. In 
silico and in vitro investigation of the antifungal activity of isoeugenol 
against Penicillium citrinum. Curr Top Med Chem 2018;18:2186-96.
89. Wils P, Warnery A, Phung-Ba V, Legrain S, Scherman D. High 
lipophilicity decreases drug transport across intestinal epithelial cells. 
J Pharmacol Exp Ther 1994;269:654-8.
90. Khanna V, Ranganathan S. Physicochemical property space 
distribution among human metabolites, drugs and toxins. BMC 
Bioinformat 2009;10:1-18.
91. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental 
and computational approaches to estimate solubility and permeability 
in drug discovery and development settings. Adv Drug Deliv Rev 
2001;46:3-26.
92. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental 
and computational approaches to estimate solubility and permeability 
in drug discovery and development settings. Adv Drug Deliv Rev 
2012;64:4-17.
93. Shearer TW, Smith KS, Diaz D, Asher C, Ramirez J. The role 
of in vitro ADME assays in antimalarial drug discovery and 
development. Comb Chem High Throughput Screen 2005;8:89-98.
94. Merlot C. Computational toxicology a tool for early safety evaluation. 
Drug Discov Today 2010;15:16-22.
95. Algahtani S. In silico ADME-Tox modeling: Progress and prospects. 
Expert Opin Drug Metab Toxicol 2017;13:1147-58.
96. Ghosh J, Lawless MS, Waldman M, Gombar V, Fraczkiewicz R. 
Modeling ADMET In silico methods for predicting drug toxicity. 
Methods Mol Biol 2016;63-83.
97. Nisha CM, Kumar A, Vimal A, Bai BM, Pal D, Kumar A. Docking 
and ADMET prediction of few GSK-3 inhibitors divulges 
6-bromoindirubin-3-oxime as potential inhibitor. J Mol Graph Model 
2016;65:100-7.
98. Horie K, Tang F, Borchardt RT. Isolation and characterization of 
Caco-2 subclones expressing high levels of multidrug resistance 
protein efflux transporter. Pharm Res 2003;20:161-7.
99. Hodgson J. ADMET-Turning chemicals into drugs. Nat Biotechnol 
2001;19:722-6.
100. Widiyarti G, Sundowo A, Megawati M, Ernawati T. Synthesis, 
characterization, anticancer and in silico ADME properties of caproic 
acid derivatives against P388 cancer cell lines. Indones J Pharm 
2019;1:1-8.
101. Stenberg P, Bergström CA, Luthman K, Artursson P. Theoretical 
predictions of drug absorption in drug discovery and development. 
Clin Pharmacokinet 2002;41:877-99.
102. Hunter J, Hirst BH. Intestinal secretion of drugs: The role of 
P-glycoprotein and related drug efflux systems in limiting oral drug 
absorption. Adv Drug Deliv Rev 1997;25:129-57.
103. Suzuki H, Sugiyama Y. Role of metabolic enzymes and efflux 
transporters in the absorption of drugs from the small intestine. Eur J 
Pharm Sci 2000;12:3-12.
104. Taipalensuu J, Törnblom H, Lindberg G, Einarsson C, Sjöqvist F, 
Melhus H, et al. Correlation of gene expression of ten drug efflux 
proteins of the ATP binding cassette family in normal human 
jejunum and in human intestinal epithelial Caco-2 cell monobyers. J 
Pharmacol Exp Ther 2001;299:164-70.
105. Pires DE, Kaminskas LM, Ascher DB. Prediction and optimization of 
pharmacokinetic and toxicity properties of the ligand. Methods Mol 
Biol 2018;1762:271-84.
106. Lin J, Sahakian DC, Morais SM, Xu JJ, Polzer RJ. Winter SM. The 
role of absorption, distribution, metabolism, excretion and toxicity in 
drug discovery. Curr Top Med Chem 2003;3:1125-54.
107. Honório KM, Moda TL, Andricopulo AD. Pharmacokinetic 
properties and in silico ADME modeling in drug discovery. Med 
Chem 2013;9:163-76.
108. Li AP. Screening for human ADME/Tox drug properties in drug 
discovery. Drug Discov Today 2001;6:357-66.
109. Silvino AC, Costa GL, Araujo FC, Ascher DB, Pires DE, Fontes CJ, 
et al. Variation in human cytochrome P-450 drug-metabolism genes: 
A gateway to the understanding of Plasmodium vivax relapses. PLoS 
One 2016;11:1-14.
110. Ekowati J, Diyah NW, Nofianti KA, Hamid IS, Sis-wodihardjo S. 
Molecular docking of ferulic acid derivatives on P2Y12 receptor and 
their ADMET prediction. J Math Fundam Sci 2018;50:203-19.
111. Shehzadi N, Hussain K, Islam M, Bukhari N, Khan MT, Salman M, 
et al. In silico drug-qualifying parameters of 5-[(4-chlorophenoxy) 
methyl]-1,3,4-oxadiazole-2-thiol. Lat Am J Pharm 2016;35:1991-7.
112. Boguslavsky J. Minimizing risk in “hits to leads”. Drug Discov Dev 
2001;4:26-30.
113. Xu C, Cheng F, Chen L, Du Z, Li W, Liu G, et al. In silico prediction 
of chemical Ames mutagenicity. J Chem Inf Model 2012;52:2840-7.
114. Sanguinetti MC, Jiang C, Curran ME, Keating MT. A mechanistic 
134
Asian J Pharm Clin Res, Vol 14, Issue 4, 2021, 124-134
 Cavalcanti et al.
link between an inherited and an acquired cardiac arrhythmia: HERG 
encodes the IKr potassium channel. Cell 1995;81:299-307.
115. Wang S, Li Y, Xu L, Li D, Hou T. Recent developments in 
computational prediction of hERG blockage. Curr Top Med Chem 
2013;13:1317-26.
116. Zhou Z, Gong Q, Ye B, Fan Z, Makielski JC, Robertson GA, et al. 
Properties of HERG channels stably expressed in HEK 293 cells 
studied at physiological temperature. Biophys J 1998;74:230-41.
117. Li F, Wang H, Wang Y, Feng S, Hu B, Zhang X, et al. Computational 
investigation reveals Picrasidine C as selective PPARα lead: Binding 
pattern, selectivity mechanism and ADME/tox profile. J Biomol 
Struct Dyn 2019;12:1-18.
118. Bissell DM, Gores GJ, Laskin DL, Hoofnagle JH. Drug-Induced liver 
injury: Mechanisms and test systems. Hepatology 2001;33:1009-13.
119. Gomez-Lechon MJ, Lahoz A, Gombau L, Castell JV, Donato MT. 
In vitro evaluation of potential hepatotoxicity induced by drugs. Curr 
Pharm Des 2010;16:1963-77.
120. Chen M, Suzuki A, Borlak J, Andrade RJ, Lucena MI. Drug-induced 
liver injury: Interactions between drug properties and host factors. J 
Hepatol 2015;63:503-14.
